All News

Virtual Musculoskeletal Care: Key Benefits for Patients, Providers, and Health Plans

August 12, 2020

Physical therapy or the regular physical activity that successful treatment of MSK disorders makes possible helps reduce the risk of many chronic conditions including type 2 diabetes, heart disease and hypertension, dementia, and mental health issues like depression and anxiety.

Medicare Part D Formularies Actually Do Encourage Use of Generics, Say Researchers

August 11, 2020

Colcrys and Copaxone are among the exceptions.

American Family Care Adopts AI Chat Solution to Answer Patient Questions on COVID

August 11, 2020

Botco.ai’s AI-powered intelligent chat solution automatically addresses questions regarding COVID-19, scheduling visits, franchising and more.

Links Between Vitamin D Deficiency and Multiple Sclerosis

August 11, 2020

Researchers reviewed the evidence of the association between vitamin D and multiple sclerosis.

Real-World Data: Psoriatic Arthritis Patients Stay on Cosentyx After Other Options Fail

August 10, 2020

A recent study found 64% of patients with psoriatic arthritis who had tried at least one biologic stayed with Cosentyx for the entire study period.

The Next Generation of PBMs: New Technology, Simpler Business Model and More Transparency

August 10, 2020

Next generation PBMs like Flipt and RxSense are challenging the "old guard" PBMs that control three-quarters of the market.

FDA Updates: Assays Used in Cancer Care Get Green Light

August 09, 2020

Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.

What Are Health Plans Doing With Their Q2 Money?

August 09, 2020

In this part two of two video series Adam Block discusses his recent article, “Profits of Publicly Traded Health Plans Surge Amid Requests for Higher Rates.”

ViiV Healthcare Receives FDA Approval for Drug to Treat Adults with HIV-1

August 08, 2020

Dovato lets adults with HIV reduce the number of antiretroviral therapies they take, while maintaining efficacy and a high barrier to resistance comparable to tenofovir-based regimens.